Voxzogo - direct healthcare professional communication (DHPC)

Vosoritide

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Direct healthcare professional communication (DHPC) : Voxzogo (vosoritide): change to administration syringe and needle leading to product administration in Units (U) instead of mL

Key facts

• Medicine name:
  Voxzogo
• Active substance:
  Vosoritide
• Therapeutic area (MeSH):
  Achondroplasia
• Procedure number:
  EMEA/H/C/005475/II/0007
• Regulatory outcome:
  Variation
• DHPC type:
  Change in dosing recommendation
• Human ATC codes:
  M05BX